<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276809</url>
  </required_header>
  <id_info>
    <org_study_id>CLL3C</org_study_id>
    <secondary_id>EU-20556</secondary_id>
    <secondary_id>MEDAC-GCLLSG-CLL3C</secondary_id>
    <nct_id>NCT00276809</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German CLL Study Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving combination chemotherapy before a peripheral blood stem cell transplant
      stops the growth of cancer cells by stopping them from dividing or killing them. Giving
      colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells
      move from the bone marrow to the blood so they can be collected and stored. A monoclonal
      antibody, such as alemtuzumab, is given to kill any remaining cancer cells. Chemotherapy and
      radiation therapy (total-body irradiation) are given to prepare the bone marrow for the stem
      cell transplant. The stem cells are then returned to the patient to replace the blood-forming
      cells that were destroyed by the chemotherapy and radiation therapy. Giving combination
      chemotherapy, total-body irradiation, and alemtuzumab together with autologous peripheral
      stem cell transplant may kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together
      with total-body irradiation and alemtuzumab works in treating patients undergoing an
      autologous stem cell transplant for stage I, stage II, stage III, or stage IV chronic
      lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the safety and feasibility of cytoreductive fludarabine and cyclophosphamide
           followed by high-dose myeloablative therapy comprising total-body irradiation,
           cyclophosphamide, and alemtuzumab in patients undergoing autologous filgrastim
           (G-CSF)-mobilized peripheral blood stem cell transplantation for stage I-IV chronic
           lymphocytic leukemia.

      Secondary

        -  Determine the clinical and molecular remission rate and duration in patients treated
           with this regimen.

        -  Determine the overall survival of patients treated with this regimen.

      OUTLINE: This is a multicenter, open label, nonrandomized study. Patients are assigned to 1
      of 2 cohorts according to time of enrollment.

        -  Cytoreductive induction therapy: All patients receive fludarabine IV and
           cyclophosphamide IV on days 1-3. Treatment repeats every 28 days for 2-4 courses in the
           absence of disease progression or unacceptable toxicity. Patients achieving complete
           response (CR) or partial response (PR) proceed to stem cell mobilization. Patients with
           stage III or IV disease at this point are removed from study.

        -  Stem cell mobilization: All patients receive Dexa-BEAM comprising oral dexamethasone
           once daily on days 1-10; carmustine IV and melphalan IV on day 2; and cytarabine IV
           twice daily and etoposide IV once daily on days 4-7. Patients also receive filgrastim
           (G-CSF) subcutaneously beginning on day 8 and continuing until leukapheresis is
           completed. Patients undergo peripheral blood stem cell (PBSC) harvest between days 20
           and 28. Patients without an adequate number of collected PBSCs may receive a second
           course of Dexa-BEAM. Patients achieving CR or very good PR proceed to high-dose
           myeloablative therapy and PBSC transplantation (PBSCT) with or without consolidation
           therapy.

        -  Consolidation therapy: Beginning between 1-2 months after completion of Dexa-BEAM,
           patients in cohort 2 receive alemtuzumab IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15,
           17, 19, 22, 24, and 26 and then proceed to high-dose myeloablative therapy and PBSCT
           within 1 month after completion of consolidation therapy. Patients in cohort 1 do not
           receive consolidation therapy and proceed directly to high-dose therapy within 3 months
           after completion of stem cell mobilization.

        -  High-dose myeloablative therapy and PBSCT: Patients undergo total-body irradiation on
           days -7 to -5. Patients then receive cyclophosphamide IV on days -4 and -3 and
           alemtuzumab IV over 2 hours on days -10, -9, -8, -6, and -4. Patients undergo PBSCT on
           day 0.

      After completion of study treatment, patients are followed periodically.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and feasibility of CAMPATH-1H included into the myeloablative regimen (cyclophosphamide and TBI) of the CLL3 protocol monitoring of treatment related mortality and morbidity (CTC scale) continuous</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate and duration of molecular responses MRD levels continuous</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and duration of clinical remissions NCIE sponsored remission criteria for CLL continuous</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time from treatment to death continuous</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Chronic lymphocytic leukemia (CLL), meeting 1 of the following stage criteria:

               -  Stage I-IV disease

               -  Binet stage B or C disease

               -  Binet stage A disease at high risk for rapid disease progression, as defined by
                  both of the following criteria:

                    -  Nonnodular marrow infiltration and/or lymphocyte doubling time &lt; 12 months

                    -  Thymidine kinase &gt; 7.0 U/L and/or ß-2-microglobulin &gt; 3.5 mg/L

          -  Polymerase chain reaction-amplifiable clonal CDR III rearrangement of the
             immunoglobulin variable heavy chain gene

          -  No Richter's syndrome or B-prolymphocytic leukemia

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  No concurrent disease resulting in major organ dysfunction

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other concurrent malignancy

          -  No New York Heart Association class III or IV cardiac failure

          -  No cardiomyopathy

          -  No history of myocardial infarction

          -  No symptomatic coronary heart disease

          -  No severe cardiac arrhythmia

          -  No severe or uncontrolled hypertension

          -  No chronic pulmonary disease

          -  No pulmonary function test impairment

          -  No severe or uncontrolled diabetes mellitus

          -  Bilirubin or transaminases ≤ 1.5 times upper limit of normal

          -  Creatinine ≤ 1.4 mg/dL

          -  No cerebral dysfunction

          -  No severe psychiatric impairment

          -  No drug addiction or alcoholism

          -  Negative HIV

          -  Negative Hepatitis B or C

          -  No allergy to any of the protocol drugs

          -  No history of anaphylactic reaction to monoclonal antibodies

          -  No active infection

        PRIOR CONCURRENT THERAPY:

          -  No more than 1 prior chemotherapy regimen OR chemotherapy that lasted &gt; 6 months

          -  No prior radiotherapy

          -  No prior treatment with alemtuzumab

          -  No prior long-term (&gt; 1 month) systemic corticosteroids

          -  No prior therapy with dexamethasone, carmustine, etoposide, cytarabine, and melphalan
             (Dexa-BEAM)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Stilgenbauer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dcllsg.de</url>
    <description>German CLL Study Group</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <keyword>stage 0 chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

